معرفی
Kristina Drott is an affiliated researcher in Medical Oncology at Lund University, focusing on epigenetic regulation in B-cell lymphomas. Her work explores how mutations in epigenetic regulators contribute to disease development and treatment resistance, aiming to restore these processes using HDAC inhibitors (e.g., Valproate) and DNA methyltransferase inhibitors.
- Leading the VALFRID trial (Diffuse Large B-cell Lymphoma) and PREVAIL trial (Chronic Lymphocytic Leukemia).
- Utilizes advanced techniques like ChIP, shRNA knockdown, and flow cytometry to study chromatin conformation and gene expression.
Her research aligns with UN Sustainable Development Goals for health and well-being. She recently co-organized a symposium on sarcoma at Lund University Cancer Centre (LUCC) in 2024.
Key collaborations include studies on Mogamulizumab’s impact on Mycosis Fungoides progression and translational biomarker projects. She works extensively with primary and cell line models to dissect epigenetic mechanisms.
